<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05025826</url>
  </required_header>
  <id_info>
    <org_study_id>RC21_0246</org_study_id>
    <nct_id>NCT05025826</nct_id>
  </id_info>
  <brief_title>Study Evaluating Neurotoxicity in Patients With Metastatic Gastro Intestinal Cancer Taking Phycocare® or Placebo During Oxaliplatin Based Chemotherapy</brief_title>
  <acronym>PROPERTY</acronym>
  <official_title>Randomized, Double-blind, Multicenter Placebo-controlled Study Evaluating Neurotoxicity in Patients With Metastatic Gastro Intestinal Cancer Taking Phycocare® or Placebo During Oxaliplatin Based Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Algosource</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most frequent side effects&#xD;
      caused by antineoplastic agents, with a prevalence from 19% to over 85%. Clinically, CIPN is&#xD;
      a mostly sensory neuropathy that may be accompanied by motor and autonomic changes of varying&#xD;
      intensity and duration.&#xD;
&#xD;
      Due to its high prevalence among cancer patients, CIPN constitutes a major problem for both&#xD;
      cancer patients and survivors as well as for their health care providers, especially because,&#xD;
      at the moment, there is no single effective method of preventing CIPN; moreover, the&#xD;
      possibilities of treating this syndrome are very limited.&#xD;
&#xD;
      The phycocyanin (PC), a biliprotein pigment and an important constituent of the blue-green&#xD;
      alga Spirulina platensis, has been reported to possess significant antioxidant and&#xD;
      radical-scavenging properties, offering protection against oxidative stress.&#xD;
&#xD;
      Study hypothesis is that phycocyanin may give protection against oxaliplatin-induced&#xD;
      neuropathy in the treatment of gastro intestinal cancers including oesogastric, colo-rectal&#xD;
      and pancreatic cancers. This trial will be a randomised placebo-controlled study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The phycocyanin used in this protocol (Phycocare®) will be 5 times more concentrated than the&#xD;
      Spirulysat (food supplement commercialized by Algosource).&#xD;
&#xD;
      It will be administrated during Oxaliplatin based chemotherapy and 3 months after oxaliplatin&#xD;
      stopped.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 5, 2021</start_date>
  <completion_date type="Anticipated">November 2024</completion_date>
  <primary_completion_date type="Anticipated">March 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Arm A: Phycocare Arm B: Placebo</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
    <masking_description>The placebo will match as much as possible all the characteristics of the Phycocare®</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Demonstrate a 50% decrease of the grade&gt; or = 2 neurotoxicity at 4 months after oxaliplatin-based chemotherapy start in the PHYCOCARE arm</measure>
    <time_frame>4 months after oxaliplatin-based chemotherapy start</time_frame>
    <description>neurotoxicity according to NCI (National Cancer Institute) criteria in both arms</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison between the two arms of percentage of patients who stopped oxaliplatin for neurological toxicity</measure>
    <time_frame>last day of chemotherapy</time_frame>
    <description>Delay of definitive interruption or decrease of oxaliplatin treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison between the two arms of percentage of patients with oxaliplatin dose decrease</measure>
    <time_frame>last day of chemotherapy</time_frame>
    <description>Dose intensity of oxaliplatin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison between the two arms of Neurological toxicities according to the Common Terminology Criteria for adverse Event (CTCAE) v5.0</measure>
    <time_frame>end of study visit (an average of 9 months after cycle 1 day1)</time_frame>
    <description>Neurological AE at following hospital visit : baseline, M4 and M9/end of study visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison between the two arms of Overall Toxicity (including hematological toxicity, gastro-intestinal toxicity, etc…)</measure>
    <time_frame>end of study visit (an average of 9 months after cycle 1 day1)</time_frame>
    <description>Adverse events grade 1 to 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison between the two arms of Patient 's Quality of Life according with EORTC-QLQ-C30</measure>
    <time_frame>end of study visit (an average of 9 months after cycle 1 day1)</time_frame>
    <description>QLQ C30 - score questions 1 to 28: score frame [30-114] . 30= good quality of life questions 29 and 30 : score frame [2-14] . 2 = bad quality of lifre</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison between the two arms of Neurological toxicities</measure>
    <time_frame>end of study visit (an average of 9 months after cycle 1 day1)</time_frame>
    <description>ElectroNeuroMyography (ENMG) and neurology questionnaire ONLS (overall neuropathy limitations scale)&#xD;
ONLS score:&#xD;
sub-score upper limbs : [0-5] . 5= worst neuropathic injury&#xD;
sub score lower limbs [0-7]: 7= worst neuropathic injury&#xD;
total score = upper limbs score + lower limbs score [0-12] ; 0= no injury; 12= maximal incapacity</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Metastatic Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>Phycocare</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PHYCOCARE during 12 cycles of 14 days from day -3 before oxaliplatin based chemotherapy until 3 months after the last dose of oxaliplatin (9 months) From D-3 to D14 before cycle 1 chemotherapy: patient will take Phycocare From D1 to D14 of cycle 2 chemotherapy and further chemotherapy cycles : patient will take Phycocare On days of chemotherapy the patient does not take Phycocare</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo during 12 cycles of 13 days from day -3 before cycle 1 of oxaliplatin based chemotherapy until 3 months after the last dose of oxaliplatin (9 months).&#xD;
From D-3 to D13 before cycle 1 chemotherapy: patient will take Placebo From D1 to D13 of cycle 2 chemotherapy and further chemotherapy cycles : patient will take Placebo.&#xD;
On days of chemotherapy the patient does not take Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Phycocare</intervention_name>
    <description>Phycocare every day during 9 months (except days of chemotherapy: no Phycocare)</description>
    <arm_group_label>Phycocare</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo every day during 9 months (except days of chemotherapy = no Placebo)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female with the age &gt; or = to 18 years old.&#xD;
&#xD;
          -  Negative pregnancy test for women with child-bearing potential if applicable (without&#xD;
             hysterectomy for example)&#xD;
&#xD;
          -  Information given to the patient who must have signed informed consent&#xD;
&#xD;
          -  Patient with Histologically or cytologically proven gastro intestinal cancer including&#xD;
             oesogastric, colo-rectal and pancreatic cancers and planned to be treated with&#xD;
             oxaliplatin&#xD;
&#xD;
          -  Patient with metastatic disease not previously treated&#xD;
&#xD;
          -  Patient willing not to take any plant-based therapy during the study (including&#xD;
             phytotherapy and gemmotherapy)&#xD;
&#xD;
          -  Previous radiotherapy is authorized if discontinued ≥15 days prior to randomization&#xD;
&#xD;
          -  Sites of disease evaluated within 42 days prior C1 day 1 of chemotherapy with&#xD;
             thoracic-abdominal-pelvic CT scan (or abdominal-pelvic MRI and chest X-ray)&#xD;
&#xD;
          -  Patient with ECOG Performance status 0 or 1&#xD;
&#xD;
          -  Patients with a Life expectancy ≥12 weeks&#xD;
&#xD;
          -  Laboratory results:&#xD;
&#xD;
        Hematologic function:&#xD;
&#xD;
        polynuclear neutrophils ≥ 1.5.109/L platelets ≥100.109/L haemoglobin ≥9 g/dL&#xD;
&#xD;
        Hepatic function:&#xD;
&#xD;
        transaminases ≤2.5 times upper limit of normal (ULN) (≤5 ULN in case of hepatic&#xD;
        metastases), alkaline phosphatases ≤2.5 x ULN (≤5 ULN in case of hepatic metastases), total&#xD;
        bilirubin ≤1.5 x ULN&#xD;
&#xD;
        Renal function:&#xD;
&#xD;
        creatinemia clearance &gt;50 ml/min (Cockcroft and Gault)&#xD;
&#xD;
        - Patient with Public Health insurance coverage&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with phenylketonuria&#xD;
&#xD;
          -  Patients with known meningeal or brain metastases&#xD;
&#xD;
          -  Patient previously treated for their metastatic cancer&#xD;
&#xD;
          -  Patient previously treated with oxaliplatin&#xD;
&#xD;
          -  Patient with specific contraindication or known hypersensitivity to spirulina&#xD;
&#xD;
          -  Patient with specific contraindication or known hypersensitivity to oxaliplatin.&#xD;
&#xD;
          -  If Patient is treated with a monoclonal antibody combined to chemotherapy (bevacizumab&#xD;
             or cetuximab or panitumumab), known allergy or hypersensitivity to antibodies or any&#xD;
             preservatives has to be excluded&#xD;
&#xD;
          -  Patient with clinically significant coronaries affection or myocardial infarction&#xD;
             within 6 months prior to randomization.&#xD;
&#xD;
          -  Patient with peripheral neuropathy &gt;1 (CTCAE scale version 5.0).&#xD;
&#xD;
          -  Patients with known dihydropyrimidine dehydrogenase (DPD) deficiency.&#xD;
&#xD;
          -  Patient with acute intestinal obstruction or sub-obstruction, history of inflammatory&#xD;
             intestinal disease or extended resection of the small intestine or presence of a colic&#xD;
             prosthesis.&#xD;
&#xD;
          -  Patient with unhealed wound, active oesogastric or duodenal ulcer, or bone fracture&#xD;
&#xD;
          -  Patient with an history of abdominal fistulas, trachea-esophageal fistulas or any&#xD;
             other grade 4, gastro-intestinal perforations or non-gastrointestinal fistulas or&#xD;
             intra-abdominal abscesses during the 6 months before randomization.&#xD;
&#xD;
          -  For patient treated with bevacizumab: patient with uncontrolled arterial hypertension&#xD;
             (systolic pressure &gt;150 mmHg and/or diastolic pressure &gt;100 mmHg) with and without&#xD;
             antihypertensive medication. Patients with high hypertension are eligible if&#xD;
             antihypertensive medication lowers their arterial pressure to the level specified by&#xD;
             the criterion.&#xD;
&#xD;
          -  Patient with an history of hypertensive crisis or hypertensive encephalopathy&#xD;
&#xD;
          -  Patient with other concomitant malignancy or history of cancer (except in situ&#xD;
             carcinoma of the cervix, or non-melanoma skin cancer, treated with curative intent&#xD;
             treatment) except if considered in complete remission for at least 2 years before&#xD;
             randomization&#xD;
&#xD;
          -  Existence of any other pathology, metabolic problem, anomaly during the clinical&#xD;
             examination or biological anomaly which may reasonable suspect an underlying pathology&#xD;
             which would contra- indicate the use of the study medication or any other risk of&#xD;
             complication related to the treatment.&#xD;
&#xD;
          -  Any treatment including an experimental drug, or participation in another clinical&#xD;
             trial within 28 days before randomization.&#xD;
&#xD;
          -  Pregnant women, or women who could possibly be pregnant (or who expect to fall&#xD;
             pregnant within 6 months of the end of treatment), or who are breast feeding are not&#xD;
             eligible.&#xD;
&#xD;
          -  Men and women of child-bearing potential who do not accept to use a highly effective&#xD;
             contraceptive (as per currently acceptable institutional standards) or abstinence&#xD;
             during the study and for the month after the last administration of the study&#xD;
             treatments.&#xD;
&#xD;
          -  Persons deprived of liberty or under guardianship.&#xD;
&#xD;
          -  Psychological, familial, sociological or geographical condition potentially hampering&#xD;
             compliance with the study protocol and follow-up schedule.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christèle LE GOUILL JAIJARAT, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NANTES UH</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christèle LE GOUILL JAIJARAT, MD</last_name>
    <phone>02 53 48 28 35</phone>
    <phone_ext>+33</phone_ext>
    <email>christèle.legouill@chu-nantes.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>DIJON UH</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Didier MAYEUR, MD-PHD</last_name>
      <email>dmayeur@cgfl.fr</email>
    </contact>
    <investigator>
      <last_name>Didier MAYEUR, MD-PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chd La Roche Sur Yon</name>
      <address>
        <city>La Roche-sur-Yon</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Paul GIROT, MD</last_name>
      <email>paul.girot@chd-vendee.fr</email>
    </contact>
    <investigator>
      <last_name>Paul GIROT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>LYON UH</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Thomas WALTER, MD-PHD</last_name>
      <email>thomas.walter@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Thomas WALTER, MD-PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nantes Uh</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Christèle LE GOUILL-JAIJARAT, MD</last_name>
      <email>christèle.legouill@chu-nantes.fr</email>
    </contact>
    <investigator>
      <last_name>Christèle LE GOUILL-JAIJARAT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Gregoire Clinique</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Clément PERRET, MD</last_name>
      <email>cl.perret@vivalto-sante.fr</email>
    </contact>
    <investigator>
      <last_name>Clément PERRET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mutaliste Clinic Saint Nazaire</name>
      <address>
        <city>Saint-Nazaire</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Catherine Ligeza- Poisson, MD</last_name>
      <email>catherine.ligeza@hospigrandouest.fr</email>
    </contact>
    <investigator>
      <last_name>Catherine Ligeza- Poisson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Foch Suresnes Hosptial</name>
      <address>
        <city>Suresnes</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Jaafar BENNOUNA, MD-PHD</last_name>
      <email>j.bennouna@hopital-foch.comm</email>
    </contact>
    <investigator>
      <last_name>Asmahane Benmaziane, MD-PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 23, 2021</study_first_submitted>
  <study_first_submitted_qc>August 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 27, 2021</study_first_posted>
  <last_update_submitted>August 23, 2021</last_update_submitted>
  <last_update_submitted_qc>August 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Oxaliplatin based chemotherapy</keyword>
  <keyword>neurotoxicity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intestinal Neoplasms</mesh_term>
    <mesh_term>Gastrointestinal Neoplasms</mesh_term>
    <mesh_term>Neurotoxicity Syndromes</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

